Addressing Drug Resistance in Cancer: A Team Medicine Approach
Authors:
- Prakash KulkarniPrakash Kulkarni
- Atish MohantyAMAtish Mohanty
- Supriyo BhattacharyaSupriyo Bhattacharya
- Sharad SinghalSSSharad Singhal
- Linlin GuoLGLinlin Guo
- Sravani RamisettySRSravani Ramisetty
- Tamara MirzapoiazovaTMTamara Mirzapoiazova
- Bolot MambetsarievBMBolot Mambetsariev
- Sandeep MittanSMSandeep Mittan
- Jyoti MalhotraJMJyoti Malhotra
- Naveen GuptaNGNaveen Gupta
- Pauline KimPKPauline Kim
Open Access
- 27 September 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5701
Abstract
Drug resistance remains one of the major impediments to treating cancer. Although many patients respond well initially, resistance to therapy typically ensues. Several confounding factors appear to contribute to this challenge. Here, we first discuss some of the challenges associated with drug resistance. We then discuss how a ‘Team Medicine’ approach, involving an interdisciplinary team of basic scientists working together with clinicians, has uncovered new therapeutic strategies. These strategies, referred to as intermittent or ‘adaptive’ therapy, which are based on eco-evolutionary principles, have met with remarkable success in potentially precluding or delaying the emergence of drug resistance in several cancers. Incorporating such treatment strategies into clinical protocols could potentially enhance the precision of delivering personalized medicine to patients. Furthermore, reaching out to patients in the network of hospitals affiliated with leading academic centers could help them benefit from such innovative treatment options. Finally, lowering the dose of the drug and its frequency (because of intermittent rather than continuous therapy) can also have a significant impact on lowering the toxicity and undesirable side effects of the drugs while lowering the financial burden carried by the patient and insurance providers.Keywords
Funding Information
- Robert and Kathleen Henderson Lung Cancer Research Accelerator Fund at the City of Hope
- William & Anna Tenenblatt Foundation
This publication has 64 references indexed in Scilit:
- Intermittent versus Continuous Androgen Deprivation in Prostate CancerNew England Journal of Medicine, 2013
- CancerDR: Cancer Drug Resistance DatabaseScientific Reports, 2013
- Intrinsically disordered proteins and conformational noiseCell Cycle, 2012
- Intermittent Androgen Suppression for Rising PSA Level after RadiotherapyNew England Journal of Medicine, 2012
- Clonal evolution in cancerNature, 2012
- Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomesIntegrative Biology, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspectiveSeminars in Cell & Developmental Biology, 2009
- Cancer genes and the pathways they controlNature Medicine, 2004
- Marcella O'Grady Boveri (1865-1950) and the chromosome theory of cancer.Journal of Medical Genetics, 1985